Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers Jun 11, 2025
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments May 13, 2025
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 Apr 29, 2025
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments Mar 31, 2025
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants Dec 20, 2024
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu Dec 5, 2024
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments Nov 8, 2024
